Related Experiment Videos

Statin treatment improves cerebral more than systemic endothelial dysfunction in patients with arterial hypertension

Janja Pretnar-Oblak1, Miran Sebestjen, Miso Sabovic

  • 1Department of Neurology, Ljubljana Medical Center, Ljubljana, Slovenia. janja.pretnar@kclj.si

American Journal of Hypertension
|May 3, 2008
PubMed

Insights

Atorvastatin treatment improved endothelial function in patients with arterial hypertension, notably enhancing cerebral circulation more than systemic circulation. This study highlights statins

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Neuroscience

Background:

  • Statins are known for pleiotropic effects on endothelial function.
  • The differential impact of statins on cerebral versus systemic circulation requires further investigation.
  • Endothelial dysfunction is a key feature of arterial hypertension.

Purpose of the Study:

  • To compare the effects of atorvastatin on cerebral and systemic endothelial function in patients with arterial hypertension (AH).
  • To assess L-arginine cerebrovascular reactivity and flow-mediated dilatation (FMD) before and after atorvastatin treatment.

Main Methods:

  • Measured L-arginine reactivity in middle cerebral arteries using transcranial Doppler sonography in AH patients and controls.
  • Assessed brachial artery flow-mediated dilatation (FMD) as a measure of systemic endothelial function.
  • Repeated measurements after 3 months of atorvastatin treatment in AH patients.

Main Results:

  • Patients with AH exhibited decreased L-arginine reactivity and FMD compared to healthy controls.
  • Atorvastatin treatment significantly improved both L-arginine reactivity and FMD in AH patients.
  • Statin therapy demonstrated a more pronounced improvement in cerebral circulation reactivity than in systemic FMD.

Conclusions:

  • Atorvastatin treatment effectively improves endothelial function, particularly cerebral reactivity, in patients with arterial hypertension.
  • The findings suggest that statins may have a greater beneficial effect on cerebral endothelial function compared to systemic endothelial function.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...